Reference Library · 62 compounds
Compound profiles.
Every research peptide we cover, graded by evidence base and tagged for UK regulatory status. Filter, sort, compare.
| Compound | Category | Evidence | UK Status | Updated |
|---|---|---|---|---|
| Dapiglutide A long-acting GLP-1/glucagon dual receptor agonist under clinical investigation for obesity and metabolic dysfunction-associated steatohepatitis (MASH) | Metabolic | Moderate | Grey area | 1 Jul 2026 |
| GHK-Cu Copper tripeptide for wound healing, tissue repair, and skin research | Healing | Moderate | Legal | 1 Jul 2026 |
| Carfilzomib Tetrapeptide epoxyketone proteasome inhibitor for relapsed multiple myeloma | Other | Strong | POM | 1 Jul 2026 |
| Bortezomib Dipeptide boronic acid proteasome inhibitor for multiple myeloma and mantle cell lymphoma | Other | Strong | POM | 1 Jul 2026 |
| Triptorelin GnRH agonist for prostate cancer, precocious puberty, and assisted reproduction | Other | Strong | POM | 1 Jul 2026 |
| Degarelix GnRH antagonist for advanced prostate cancer — immediate androgen deprivation without a testosterone flare | Other | Strong | POM | 1 Jul 2026 |
| Cetrorelix GnRH antagonist used in assisted reproduction to prevent premature ovulation | Other | Strong | POM | 1 Jul 2026 |
| Noopept Dipeptide-derived nootropic with neurotrophic (BDNF/NGF) and cognitive-enhancing properties | Cognitive | Moderate | Grey area | 1 Jul 2026 |
| MOTS-c Mitochondrial-derived peptide with metabolic and exercise-mimetic properties | Metabolic | Limited | Grey area | 1 Jul 2026 |
| Somatorelin (GHRH 1-44) Endogenous growth hormone-releasing hormone (GHRH 1-44) — the native peptide template for sermorelin, CJC-1295 and tesamorelin | Growth hormone | Moderate | Grey area | 1 Jul 2026 |
| Relaxin-2 (Serelaxin) Antifibrotic and vasodilatory peptide investigated for acute heart failure and fibrotic disease | Healing | Moderate | Grey area | 1 Jul 2026 |
| Oxyntomodulin Dual GLP-1/glucagon receptor agonist peptide for weight loss and metabolic research | Metabolic | Moderate | Grey area | 1 Jul 2026 |
| Thymalin Thymus-derived immunomodulatory peptide for research into immune regulation and ageing | Longevity | Moderate | Grey area | 1 Jul 2026 |
| Carperitide A recombinant human atrial natriuretic peptide (hANP) for acute heart failure — approved in Japan, unlicensed elsewhere | Other | Moderate | Legal | 1 Jul 2026 |
| Plitidepsin A marine-derived cyclic depsipeptide targeting eEF1A2 — anticancer and host-directed antiviral applications | Other | Moderate | Legal | 1 Jul 2026 |
| Romidepsin A cyclic depsipeptide HDAC inhibitor approved for cutaneous and peripheral T-cell lymphoma | Other | Strong | POM | 1 Jul 2026 |
| Etelcalcetide A D-amino acid peptide allosteric activator of the calcium-sensing receptor for secondary hyperparathyroidism | Other | Strong | POM | 1 Jul 2026 |
| Apraglutide A long-acting GLP-2 receptor agonist for short bowel syndrome with intestinal rehabilitation potential | Other | Strong | POM | 1 Jul 2026 |
| Copper Peptides An overview of copper-binding peptide complexes — GHK-Cu, AHK-Cu and beyond — and their role in wound healing, skin repair and regenerative research | Skin & hair | Moderate | Legal | 1 Jul 2026 |
| Davunetide (AL-108) A neuroprotective octapeptide from ADNP investigated for tauopathies, cognitive decline, and progressive supranuclear palsy — reached Phase 3 clinical trials | Cognitive | Moderate | Grey area | 1 Jul 2026 |
| Larazotide Acetate A tight-junction-modulating peptide investigated for celiac disease, inflammatory bowel disease, and gut-barrier research | Healing | Moderate | Grey area | 1 Jul 2026 |
| Plecanatride Synthetic uroguanylin analogue and GC-C receptor agonist used in research for constipation disorders and intestinal inflammation models | Other | Strong | POM | 1 Jul 2026 |
| Goserelin Synthetic GnRH agonist used in research for hormone-sensitive cancers, endometriosis, and reproductive biology models | Other | Strong | POM | 1 Jul 2026 |
| Leuprolide Synthetic GnRH agonist used in research for hormone-dependent conditions, prostate cancer models, and pubertal suppression studies | Other | Strong | POM | 1 Jul 2026 |
| Glatiramer Acetate Synthetic peptide polymer used in research for its immunomodulatory effects in multiple sclerosis and autoimmune models | Other | Strong | POM | 1 Jul 2026 |
| Desmopressin Synthetic vasopressin analogue used in research for bleeding disorders, nocturia, and diabetes insipidus | Other | Strong | POM | 1 Jul 2026 |
| Bivalirudin Synthetic hirudin-derived direct thrombin inhibitor licensed for anticoagulation during percutaneous coronary intervention | Other | Strong | POM | 1 Jul 2026 |
| Eptifibatide Venom-derived cyclic heptapeptide GPIIb/IIIa inhibitor licensed for acute coronary syndromes and percutaneous coronary intervention | Other | Strong | POM | 1 Jul 2026 |
| Pasireotide Second-generation somatostatin analogue with high SST5 affinity — licensed for Cushing's disease and refractory acromegaly | Metabolic | Strong | POM | 1 Jul 2026 |
| Lanreotide Long-acting somatostatin analogue licensed for acromegaly and neuroendocrine tumours, with emerging research in polycystic kidney disease | Metabolic | Strong | POM | 1 Jul 2026 |
| Aviptadil Synthetic vasoactive intestinal peptide (VIP) with investigated efficacy in acute respiratory distress and pulmonary fibrosis | Other | Moderate | POM | 1 Jul 2026 |
| Efepoetin Alfa EPO-mimetic peptide for anaemia in chronic kidney disease | Other | Strong | POM | 1 Jul 2026 |
| Balixafortide CXCR4 antagonist peptide for metastatic breast cancer | Other | Moderate | POM | 1 Jul 2026 |
| Romiplostim Thrombopoietin receptor agonist peptibody for immune thrombocytopenia | Other | Strong | POM | 1 Jul 2026 |
| Glepaglutide Long-acting GLP-2 analogue for short bowel syndrome | Metabolic | Strong | POM | 1 Jul 2026 |
| Difelikefalin Selective kappa-opioid receptor agonist for chronic kidney disease–associated pruritus | Other | Strong | POM | 1 Jul 2026 |
| Buserelin GnRH agonist — prostate cancer, endometriosis, IVF, and the biphasic pituitary response | Other | Strong | POM | 1 Jul 2026 |
| Avexitide GLP-1 receptor antagonist for hyperinsulinaemic hypoglycaemia — mechanism, evidence, and research context | Metabolic | Moderate | Grey area | 1 Jul 2026 |
| Teriparatide PTH(1-34) fragment — bone formation, osteoporosis, and fracture healing research | Healing | Strong | POM | 1 Jul 2026 |
| Octreotide Somatostatin analogue — acromegaly, neuroendocrine tumours, and research applications | Other | Strong | POM | 1 Jul 2026 |
| Setmelanotide MC4R agonist peptide for rare genetic obesity — mechanism, evidence, and research context | Metabolic | Strong | POM | 1 Jul 2026 |
| Ziconotide A cone snail-derived conopeptide blocking N-type calcium channels — the first and only intrathecal peptide analgesic | Other | Strong | POM | 1 Jul 2026 |
| Linaclotide A 14-amino-acid GC-C agonist for IBS-C — a locally acting oral peptide with negligible systemic absorption | Other | Strong | POM | 1 Jul 2026 |
| Teduglutide A GLP-2 analogue for short bowel syndrome — the first approved peptide targeting intestinal adaptation | Other | Strong | POM | 1 Jul 2026 |
| Lixisenatide A once-daily GLP-1 receptor agonist derived from exendin-4, with strong prandial glucose control | Metabolic | Strong | POM | 1 Jul 2026 |
| Exenatide The first incretin mimetic — synthetic exendin-4 that established the GLP-1 receptor agonist class | Metabolic | Strong | POM | 1 Jul 2026 |
| TB-500 Forte A higher-concentration vendor variant of TB-500 (synthetic Thymosin Beta-4), not a chemically distinct peptide | Healing | Limited | Grey area | 1 Jul 2026 |
| EC508 An investigational dynorphin A-based analgesic peptide designed as a non-opioid pain therapeutic | Other | Limited | Grey area | 1 Jul 2026 |
| ACE-031 A recombinant ActRIIB-Fc decoy receptor developed as a myostatin inhibitor, discontinued after Phase 2 safety concerns | Body composition | Moderate | Grey area | 1 Jul 2026 |
| Follistatin-344 A myostatin-binding glycoprotein researched for muscle growth, fibrosis inhibition, and tissue repair | Body composition | Limited | Grey area | 1 Jul 2026 |
| Leuphasyl (Pentapeptide-18) An enkephalin-modulating cosmetic peptide researched for anti-wrinkle effects via facial muscle relaxation | Skin & hair | Limited | Legal | 1 Jul 2026 |
| Snap-8 (Acetyl Octapeptide-3) A next-generation topical neuropeptide and Argireline analogue that inhibits SNARE complex formation to reduce expression lines | Skin & hair | Limited | Legal | 1 Jul 2026 |
| Argireline (Acetyl Hexapeptide-8) A topical neuropeptide that reduces wrinkle formation by inhibiting neurotransmitter release — often called 'Botox in a bottle' | Skin & hair | Limited | Legal | 1 Jul 2026 |
| Matrixyl (Palmitoyl Pentapeptide-4) A widely used cosmetic matrikine peptide that stimulates collagen synthesis for anti-ageing and skin repair research | Skin & hair | Limited | Legal | 1 Jul 2026 |
| Danuglipron Pfizer's oral GLP-1 receptor agonist for obesity and type 2 diabetes — discontinued from Phase 3 development | Metabolic | Moderate | POM | 1 Jul 2026 |
| BPC-157 Arginate A stabilised salt form of BPC-157 with improved shelf-life and oral bioavailability for research applications | Healing | Limited | Grey area | 1 Jul 2026 |
| Melanotan I (Afamelanotide) Alpha-MSH analogue EMA-approved for erythropoietic protoporphyria, investigated for photoprotection | Skin & hair | Moderate | POM | 1 Jul 2026 |
| Gonadorelin Synthetic GnRH decapeptide used for HPG axis diagnostics and hypothalamic hypogonadism treatment | Other | Moderate | POM | 1 Jul 2026 |
| Oxytocin Neurohypophysial hormone investigated for social bonding, stress modulation, and metabolic effects | Other | Moderate | POM | 1 Jul 2026 |
| DSIP (Delta Sleep-Inducing Peptide) Neuropeptide investigated for sleep regulation, stress adaptation, and physiological recovery | Sleep | Limited | Grey area | 30 Jun 2026 |
| Tesofensine Triple monoamine reuptake inhibitor investigated for obesity and neurodegenerative conditions | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| SLU-PP-332 Synthetic ERR agonist and exercise mimetic peptide with preclinical evidence for metabolic enhancement and fat loss | Metabolic | Limited | Grey area | 30 Jun 2026 |
| Glutathione Endogenous tripeptide antioxidant with clinical evidence for oxidative stress reduction and potential skin-lightening effects | Longevity | Moderate | Grey area | 30 Jun 2026 |
| AHK-Cu Copper-binding tripeptide with in vitro evidence for hair growth stimulation and wound healing | Skin & hair | Limited | Grey area | 30 Jun 2026 |
| ARA-290 (Cibinetide) Helix B surface peptide and EPO receptor agonist with clinical evidence in neuropathy and inflammatory conditions | Healing | Moderate | Grey area | 30 Jun 2026 |
| KPV Anti-inflammatory tripeptide derived from alpha-MSH with preclinical evidence in intestinal and systemic inflammation | Healing | Limited | Grey area | 30 Jun 2026 |
| Pinealon Short tripeptide bioregulator targeting pineal gland function, circadian rhythm, and cognitive ageing | Cognitive | Limited | Grey area | 30 Jun 2026 |
| NAD+ Essential cellular coenzyme central to energy metabolism, DNA repair, and longevity research | Longevity | Moderate | Grey area | 30 Jun 2026 |
| Cerebrolysin Peptide hydrolysate preparation with neuroprotective and neurotrophic effects, investigated for stroke, TBI, and cognitive decline | Cognitive | Moderate | POM | 30 Jun 2026 |
| Thymosin Beta-4 Naturally occurring 43-amino-acid peptide with wound-healing, anti-inflammatory, and tissue-repair properties | Healing | Moderate | Grey area | 30 Jun 2026 |
| PT-141 (Bremelanotide) Melanocortin receptor agonist investigated for sexual dysfunction and arousal disorders | Other | Moderate | POM | 30 Jun 2026 |
| Orforglipron First orally available GLP-1 receptor agonist approved for obesity — a small-molecule peptide mimetic | Fat loss | Strong | Grey area | 30 Jun 2026 |
| BPC-157 Synthetic pentadecapeptide researched for tissue repair, wound healing, and anti-inflammatory effects | Healing | Limited | Grey area | 30 Jun 2026 |
| Survodutide GLP-1/glucagon dual receptor agonist under investigation for obesity and MASH | Metabolic | Moderate | Grey area | 30 Jun 2026 |
| CagriSema Investigational cagrilintide + semaglutide combination therapy — REDEFINE-2 Phase 3 results published in NEJM 2025 show superior weight loss vs semaglutide alone | Fat loss | Moderate | POM | 30 Jun 2026 |
| Semaglutide Selective GLP-1 receptor agonist for type 2 diabetes and obesity — now directly compared with tirzepatide in the landmark SURMOUNT-5 trial | Fat loss | Strong | POM | 30 Jun 2026 |
| Tirzepatide Dual GIP/GLP-1 receptor agonist for type 2 diabetes and obesity — the first incretin to demonstrate superiority over semaglutide in a head-to-head trial | Fat loss | Strong | POM | 30 Jun 2026 |
| Amycretin A first-in-class dual GLP-1 and amylin receptor agonist in early clinical development for obesity | Fat loss | Limited | Grey area | 30 Jun 2026 |
| VK2735 A dual GIP/GLP-1 receptor agonist in clinical development for obesity and weight management | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| Retatrutide Triple GLP-1/GIP/glucagon receptor agonist showing up to 28.7% weight loss in Phase 3 trials | Fat loss | Strong | POM | 30 Jun 2026 |
| Maridebart Cafraglutide (MariTide) A GLP-1 receptor agonist / GIP receptor antagonist peptide in Phase 2 development for obesity | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| Pemvidutide GLP-1/glucagon dual agonist investigational peptide for MASH and obesity | Metabolic | Moderate | Grey area | 30 Jun 2026 |
| Petrelintide A long-acting amylin analogue in Phase 2 development for obesity | Fat loss | Limited | Grey area | 30 Jun 2026 |
| Ecnoglutide A biased GLP-1 receptor agonist in Phase 3 development for obesity and type 2 diabetes | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| Semax A synthetic ACTH analogue studied for cognitive enhancement and neuroprotection | Cognitive | Limited | Legal | 30 Jun 2026 |
| Selank A synthetic tuftsin analogue studied for anxiolytic and cognitive effects | Cognitive | Limited | Legal | 30 Jun 2026 |
| Dihexa An angiotensin IV-derived peptide studied for cognitive enhancement and synaptogenesis | Cognitive | Limited | Legal | 30 Jun 2026 |
| Cagrilintide Long-acting amylin analogue in development as CagriSema (with semaglutide) for obesity and type 2 diabetes | Fat loss | Moderate | Grey area | 30 Jun 2026 |
| LL-37 Human cathelicidin antimicrobial peptide with broad-spectrum antimicrobial and immunomodulatory properties | Healing | Moderate | Legal | 30 Jun 2026 |
| Thymosin Alpha-1 An immune-modulating peptide with a long clinical history in viral hepatitis and emerging interest in oncology and autoimmune research | Other | Moderate | Grey area | 30 Jun 2026 |
| HGH Fragment 176-191 A modified C-terminal fragment of human growth hormone investigated for selective lipolytic effects without the broader metabolic actions of full-length hGH | Fat loss | Limited | Grey area | 30 Jun 2026 |
| GHRP-2 A synthetic growth hormone secretagogue that stimulates GH release via the ghrelin receptor — used in research to study growth hormone deficiency and body composition | Growth hormone | Moderate | Grey area | 30 Jun 2026 |
| PEG-MGF PEGylated Mechano Growth Factor — a modified splice variant of IGF-1 researched for muscle repair and recovery | Body composition | Limited | Grey area | 30 Jun 2026 |
| Liraglutide GLP-1 receptor agonist: the first daily weight-loss peptide to reach clinical approval | Metabolic | Strong | POM | 30 Jun 2026 |
| GHRP-6 A foundational growth hormone-releasing peptide studied for GH secretion, appetite stimulation, and synergy with GHRH analogues | Growth hormone | Moderate | Grey area | 30 Jun 2026 |
| Hexarelin A potent synthetic growth hormone-releasing peptide (GHRP) studied for its effects on GH secretion, cardiac function, and body composition | Growth hormone | Moderate | Grey area | 30 Jun 2026 |
| Mazdutide Dual GLP-1/glucagon receptor agonist in clinical development for obesity and type 2 diabetes | Fat loss | Moderate | POM | 30 Jun 2026 |
| Tesamorelin Growth hormone-releasing hormone analogue for HIV-associated lipodystrophy | Growth hormone | Strong | POM | 30 Jun 2026 |
| Kisspeptin A neuropeptide governing reproductive hormone signalling, with emerging clinical research in endocrinology | Other | Moderate | Legal | 30 Jun 2026 |
| 5-Amino-1MQ An NNMT inhibitor peptide researched for fat loss and metabolic function | Fat loss | Limited | Legal | 30 Jun 2026 |
| Epitalon Synthetic tetrapeptide studied for telomere lengthening and anti-ageing effects | Longevity | Limited | Legal | 30 Jun 2026 |
| Sermorelin Growth hormone-releasing hormone (GHRH) analog used in research to stimulate endogenous GH production | Growth hormone | Moderate | Legal | 30 Jun 2026 |
| Elamipretide (SS-31) A mitochondria-targeted peptide under investigation for primary mitochondrial myopathy, Barth syndrome, and cardiorenal disease | Longevity | Moderate | Grey area | 30 Jun 2026 |
| Melanotan II Melanocortin receptor agonist researched for tanning and sexual function effects | Skin & hair | Moderate | Grey area | 29 Jun 2026 |
| AOD-9604 Modified hGH fragment peptide researched for targeted fat metabolism | Fat loss | Moderate | Legal | 29 Jun 2026 |
| CJC-1295 Long-acting GHRH analogue studied for sustained growth hormone elevation | Growth hormone | Moderate | Legal | 29 Jun 2026 |
| Ipamorelin Selective growth hormone secretagogue studied for GH release, body composition, and recovery | Growth hormone | Limited | Legal | 29 Jun 2026 |
| TB-500 Synthetic thymosin beta-4 fragment studied for tissue repair, wound healing, and anti-inflammatory effects | Healing | Limited | Legal | 29 Jun 2026 |